Electrochemiluminescence (ECL) · High Sensitivity

Drug-Tolerant Bridging Format

MSD Anti-Drug Antibody (ADA) & Immunogenicity Testing Services

Q: What is the difference between ADA and neutralizing antibodies (NAb)?

ADA (binding antibodies): all antibodies that bind to the drug, detected by Tier 1/2 bridging assays. NAb (neutralizing antibodies): the subset of ADA that block drug biological activity. All NAbs are ADA, but not all ADA are NAbs. Clinical significance depends on neutralizing activity, titer magnitude, and persistence.

Detect and characterize anti-drug antibodies with Electrochemiluminescence (ECL) — acid-dissociation bridging format for drug-tolerant ADA detection, higher sensitivity than ELISA, and the same platform as your PK assay for integrated preclinical and clinical immunogenicity assessment.

Immunogenicity can neutralize drug activity, alter pharmacokinetics, or trigger hypersensitivity — making sensitive ADA detection critical from candidate selection through post-marketing surveillance. MSD addresses the core ADA challenge: detecting low-titer antibodies in the presence of high circulating drug concentrations. The acid-dissociation bridging format disrupts drug-ADA complexes at low pH, enabling total ADA detection even when drug levels would mask ADA in standard ELISA. For multi-domain therapeutics (ADCs, bispecifics), multiplex capability enables simultaneous screening for ADA against Fab, Fc, and payload in a single 25 µL sample.

Inquire About ADA Testing Tiered Testing Approach

The ADA Detection Challenge — Sensitivity Meets Drug Tolerance

Anti-drug antibodies present a fundamental bioanalytical paradox: they must be detected in the presence of the drug that they bind. At therapeutic drug concentrations, circulating drug occupies ADA binding sites, preventing the bridging interaction that the assay depends on. A negative ADA result may reflect true ADA absence, or drug interference masking ADA that is actually present. Drug-tolerant ADA assays address this through acid-dissociation: samples are acidified to pH ~2.5–3.0 to transiently dissociate drug-ADA complexes, then neutralized in the presence of excess labeled drug, capturing total ADA. MSD's solution-phase bridging kinetics and low background make it the platform of choice for drug-tolerant ADA detection.

 The Multi-Tiered ADA Testing Paradigm
Tier 1 — Screening: high-sensitivity bridging assay detecting all ADA isotypes (IgG, IgM, IgA, IgE). Cut point established from 50+ drug-naive donor samples. Must minimize false negatives.
Tier 2 — Confirmatory: competitive inhibition with excess unlabeled drug to demonstrate ADA specificity. Signal inhibition above a confirmatory cut point confirms ADA specificity.
Tier 3 — Titer & NAb: serial dilution endpoint titer and neutralizing antibody assessment (competitive ligand-binding or cell-based) to determine clinical relevance.

Tiered ADA Testing Strategy

Tier 1: Screening Assay

Bridging format with biotinylated drug + SULFO-TAG-labeled drug. Cut point at 95th percentile of drug-naive donor population. High sensitivity configuration to minimize false negatives. ECL's low background enables lower cut points than ELISA.

Tier 2: Confirmatory Assay

Competitive inhibition — re-test screening-positive samples with and without excess unlabeled drug. Confirmatory cut point typically 20–30% signal inhibition. Non-enzymatic ECL detection eliminates drug interference with colorimetric readout.

Tier 3: Titer & NAb

Serial dilution endpoint titer for confirmed positive samples. Neutralizing antibody assessment by competitive ligand-binding (MSD-based) or cell-based assay depending on drug mechanism of action.

Why MSD Outperforms ELISA for ADA

ECL Advantages for Immunogenicity Testing

Higher sensitivity: ECL bridging achieves ~10–100 ng/mL ADA sensitivity vs. ~50–500 ng/mL for ELISA — detecting ADA at lower titers and earlier timepoints.
Superior drug tolerance: acid-dissociation in solution phase enables more complete drug-ADA complex disruption and re-capture than solid-phase ELISA formats.
Lower background: SULFO-TAG emits only at the electrode surface — unbound labeled drug in solution generates zero background. ELISA's enzyme-substrate reactions produce non-specific signal that elevates background.
Multi-domain ADA in one well: for ADCs and bispecifics, screen for anti-Fab, anti-Fc, and anti-payload ADA simultaneously from 25 µL.

Method Development & Qualification

Positive control: anti-drug polyclonal or monoclonal antibody, affinity-purified, characterized for use throughout assay lifecycle.
Cut point determination: 50+ individual drug-naive donor matrix samples, multi-run/multi-analyst evaluation.
Drug tolerance: maximum drug concentration at which low-positive control ADA is consistently detected — defines the reportable ADA window in context of expected PK concentrations.
Parameters documented: sensitivity, selectivity, precision, drug tolerance, hook effect, freeze-thaw stability.

ADA Testing Service Details

Service Package

Item	Full Service	Notes
Method Development	Included	Reagent labeling, acid-dissociation optimization
Cut Point Determination	Included	50+ donor matrix panel
Tier 1 Screening	Bridging ECL	With positive/negative controls
Tier 2 Confirmation	Competition format	Excess unlabeled drug
Tier 3 Titer	Serial dilution	Endpoint titer for confirmed positives

For Research Use Only. Assays use manufacturer-validated MSD reagents with documented QC protocols.

How to Get Started

Consult

Provide drug info, expected therapeutic levels, and development stage. We'll recommend the optimal ADA strategy.

Method Development

Reagent preparation, acid-dissociation optimization, cut point determination, and qualification.

Sample Analysis

Tiered testing with full documentation. ADA incidence, titer, and NAb data with comprehensive QC metrics.

ADA Detection: MSD vs ELISA

Feature	MSD (Bridging)	ELISA (Bridging)
Sensitivity	~10–100 ng/mL	~50–500 ng/mL
Drug Tolerance	High — acid dissociation in solution phase	Low–moderate — solid-phase steric hindrance
Multi-Domain ADA	Yes — Fab + Fc + payload in one well	No — separate assays per domain
Sample Volume	25 µL	100 µL
Same Platform as PK	Yes — shared reagents, one instrument	Possible — same plate format

What You Receive

Tiered ADA report — screening, confirmatory, and titer data with per-tier QC metrics (Excel + PDF)
Cut point documentation — SCP and CCP with donor demographics and statistical methodology
Raw ECL data — per-well signal values, S/N ratios, plate maps
Drug tolerance data — documented drug tolerance limit for your therapeutic
Methods summary — formatted for bioanalytical reports with acid-dissociation protocol

Why Choose Electrochemiluminescence for ADA Testing

Drug-tolerant ADA that ELISA cannot match: acid-dissociation in solution phase enables ADA detection at therapeutic drug levels where ELISA reports false negatives
Same platform, same reagents as PK: SULFO-TAG-labeled drug used for both PK and ADA — one qualification supports both assays
Multi-domain ADA in one well: screen anti-Fab, anti-Fc, and anti-payload simultaneously from 25 µL for ADCs and bispecifics
Lower background = better cut point discrimination: ECL's electrode-proximal signal eliminates unbound reagent background — superior S/N vs ELISA
Screening-through-titer on one format: same bridging configuration for Tier 1/2/3 — no format-switching variability

ADA Testing FAQ

What is the difference between ADA and neutralizing antibodies (NAb)?

ADA (binding antibodies): all antibodies that bind to the drug, detected by Tier 1/2 bridging assays. NAb (neutralizing antibodies): the subset of ADA that block drug biological activity. All NAbs are ADA, but not all ADA are NAbs. Clinical significance depends on neutralizing activity, titer magnitude, and persistence.

How does acid-dissociation enable drug-tolerant ADA detection?

Standard ADA bridging fails when circulating drug occupies both ADA binding arms. Acid-dissociation (pH ~2.5–3.0, 30–60 min) transiently unfolds drug-ADA complexes. Upon neutralization in the presence of excess biotinylated + SULFO-TAG-labeled drug, total ADA is captured as it refolds. MSD's solution-phase kinetics enable efficient re-capture after neutralization, outperforming solid-phase ELISA.

Can PK and ADA share reagents on the MSD platform?

Yes — the same SULFO-TAG-labeled drug used for PK detection can be used for ADA bridging. Both assays require only 25 µL, run on the same instrument, and can be analyzed in the same batch. This reagent sharing simplifies supply chain and ensures analytical continuity between PK and ADA data.

Inquiry Basket